Jubilant Pharma develops oral formulation of Remdesivir

April 19, 2021 10:26 pm | Updated 10:26 pm IST - MUMBAI

Jubilant Pharma Ltd., a subsidiary of Jubilant Pharmova Ltd., has announced the successful completion of safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral formulation of Remdesivir. The drug is currently commercially available as an injectable formulation and is being used in the treatment of COVID-19.

Jubilant has sought authorisation for additional studies for this formulation from the Drug Controller General of India (DCGI). The proposed oral treatment is expected to lastbe for five days, a duration similar to the injectable dosage form.

“It is specifically designed to avoid hepatic metabolism which results in almost complete first-pass clearance/elimination of Remdesivir when it is administered by the traditional oral route. The findings from both preclinical and human studies indicate that the drug is able to undergo absorption when administered using the novel oral formulation,” the company said in a statement.

“The novel formulation was well tolerated by all the study subjects with no additional safety/ tolerability profile as compared to the injectable product,” it said.

In May 2020, Jubilant entered into a non-exclusive licensing agreement with Gilead Sciences, Inc. that had granted it the right to register, manufacture and sell Gilead’s Remdesivir in 127 countries, including India.

On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the antiviral drug remdesivir (JUBI-R) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19.

“Once approved, this will not only provide a more convenient and easy-to-administer formulation but also support an increasing demand of COVID-19 treatments.” said Shyam S. Bhartia, chairman and Hari S. Bhartia, co-chairman and MD, Jubilant Pharmova Ltd.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.